[BMY] Bristol-Myers Squibb Company

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 128.21 B

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 59.6 Change: 0.82 (1.4%)
Ext. hours: Change: 0 (0%)

chart BMY

Refresh chart

Strongest Trends Summary For BMY

BMY is in the long-term down -29% below S&P in 2 years and up 231% in 22 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company?s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding1.67 B EPS2.51 EPS Growth - 4 Quarters-704.03% EPS Growth - Q/Q-233.04%
EPS Growth - Y/Y-255.12% Sales Growth - 4 Quarters 6.17% Sales Growth - Q/Q3.02% P/E21.7
P/E To EPS Growth0.28 P/S7.83 P/BV8.48 Price/Cash Per Share23.41
Price/Free Cash Flow48.9 ROA5.6% ROE11.84% ROI7.56%
Current Ratio1.76 Quick Ratio1.58 Long Term Debt/Equity1.18 Debt Ratio0.49
Gross Margin76.6% Operating Margin14.94% Net Profit Margin10.93% Dividend Payout Ratio-136.15%
Dividend Yield-1.9%
Fundamental Data
Cash From Financing Activities-1.57 B Cash From Investing Activities-526 M Cash From Operating Activities697 M Gross Profit3.18 B
Net Profit-130 M Operating Profit45 M Total Assets31.95 B Total Current Assets13.06 B
Total Current Liabilities7.44 B Total Debt7.37 B Total Liabilities16.83 B Total Revenue4.16 B
Technical Data
High 52 week62.66 Low 52 week42.77 Last close47.32 Last change0.06%
RSI79.2 Average true range1.11 Beta0.67 Volume5.04 M
Simple moving average 20 days5.46% Simple moving average 50 days3.65% Simple moving average 200 days-1.71%
Performance Data
Performance Week2.89% Performance Month6.27% Performance Quart1.55% Performance Half-4.95%
Performance Year-20.85% Performance Year-to-date-8.14% Volatility daily1.49% Volatility weekly3.34%
Volatility monthly6.85% Volatility yearly23.72% Relative Volume180.93% Average Volume13.49 M
New High New Low

News

2019-11-17 15:40:35 | AbbVie's Humira on Pace to Become Biggest Seller by 2024

2019-11-15 18:39:00 | Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

2019-11-15 17:43:00 | FTC makes Celgene's Otezla divestiture official condition for Bristol-Myers acquisition

2019-11-15 17:28:20 | Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday

2019-11-15 17:18:42 | UPDATE 2-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

2019-11-15 17:00:11 | Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

2019-11-15 16:55:00 | Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition

2019-11-15 07:12:12 | Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

2019-11-15 06:41:11 | 4 Big Drugmakers to Bet on After a Great Earnings Season

2019-11-15 05:00:00 | Bristol-Myers Squibb- A Beaten-Up Buy

2019-11-14 09:44:02 | Celldex CLDX Q3 Loss Narrower Than Expected, Revenues Miss

2019-11-13 13:14:06 | AVEO Pharmaceuticals AVEO Q3 Earnings & Revenues Top Mark

2019-11-12 10:03:56 | The Extreme Risks of Trading Your Own Retirement Assets - November 12, 2019

2019-11-12 07:59:12 | Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review

2019-11-12 06:59:00 | Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

2019-11-11 16:25:46 | Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug?

2019-11-11 16:23:09 | Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study

2019-11-11 09:28:02 | 4 Biotech Stocks That Could Keep Beating Wall Street

2019-11-11 09:09:02 | Want To Retire Early? Learn the Intelligent Investing Secret - November 11, 2019

2019-11-11 09:05:02 | Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug

2019-11-11 08:55:00 | Nektar Therapeutics Stock Is Rising on Test Data for Cancer Drug

2019-11-11 08:46:01 | Novartis' Generics Unit to Buy Aspen's Japanese Operations

2019-11-11 06:59:00 | U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo nivolumab Plus Yervoy ipilimumab Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma

2019-11-08 14:24:00 | Celgene's rare disease drug gets FDA approval

2019-11-08 09:32:02 | Clovis CLVS Q3 Earnings & Sales Beat Estimates, Shares Up

2019-11-08 09:26:02 | Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

2019-11-08 05:13:28 | Have Bristol-Myers Squibb Company NYSE:BMY Insiders Been Selling Their Stock?

2019-11-07 13:06:10 | P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's confirms Bristol-Myers Squibb at A2; negative outlook

2019-11-07 11:13:04 | Nektar NKTR Q3 Earnings & Revenues Top Estimates, Stock Up

2019-11-07 10:49:03 | Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb

2019-11-07 06:59:00 | Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® abatacept in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting1

2019-11-07 06:58:00 | Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

2019-11-06 09:31:29 | 5 Stocks With Solid Sales Growth to Keep an Eye on Right Now

2019-11-05 18:16:26 | Vanguard Health Care Fund Sells Out of Allergan

2019-11-05 10:11:03 | The Zacks Analyst Blog Highlights: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard and Bristol-Myers Squibb

2019-11-05 06:59:00 | Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes

2019-11-04 17:05:10 | Biotech ETFs in Focus on Impressive Q3 Earnings Results

2019-11-04 13:00:06 | Value Biotech ETFs & Stocks to Buy Now

2019-11-04 11:10:04 | The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

2019-11-04 10:47:32 | The Extreme Risks of Trading Your Own Retirement Assets - November 04, 2019

2019-11-04 09:07:02 | 5 High-Flying Stocks Near 52-Week High That Can Scale Higher

2019-11-01 11:33:54 | 2 Health Stocks With Gains Thursday

2019-11-01 11:18:54 | Two Trending healthcare stocks with a strong pulse.

2019-11-01 10:55:02 | Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

2019-11-01 10:07:00 | Celgene Stock Has Soared. One Analyst Says It’s Too Expensive Now.

2019-11-01 10:00:02 | Company News for Nov 1, 2019

2019-11-01 09:25:01 | Simple Secrets Anyone Can Use to Reach Early Retirement - November 01, 2019

2019-11-01 09:15:01 | Bristol-Myers BMY Hits Fresh High: Is There Still Room to Run?

2019-11-01 08:45:12 | 3 Reasons Growth Investors Will Love Bristol-Myers BMY

2019-11-01 06:59:00 | Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes